Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR ...

This article provides a thorough overview of the pathophysiology and current treatment options for myasthenia gravis, an autoimmune and antibody-mediated neuromuscular disease.

Thymectomy for Myasthenia Gravis: Predicting Outcomes —A retrospective analysis of patients with acetylcholine receptor antibody (AChR-Ab)-positive generalized myasthenia gravis (MG) who ...

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

Advances in the Treatment of Myasthenia Gravis Nils Erik Gilhus Disclosures Future Neurology. 2012;7 (6):701-708. Pathogenesis MG patients should always be diagnosed according to disease subgroup.

Marla Black Morgan, MD, looks to the future of research in both myasthenia gravis and rare neurological disorders by expanding data collection and identifying areas of potential difference in ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

The patients serum contained antibodies against striated muscle 11 (titer of 1:480), which occur in nearly all patients with myasthenia gravis and thymoma, but also occur in 25 per cent of cases ...

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate to severe atopic dermatitis, meeting its primary and secondary ...